Urinary estrogen metabolites and prostate cancer risk: A pilot study

Prostate

Volumn 71, Issue 5, 2011, Pages 507-516

  Kosti, Ourania ^a   Xu, Xia ^b   Veenstra, Timothy D ^b   Hsing, Ann W ^c   Chu, Lisa W ^c   Goldman, Lenka ^a   Bebu, Ionut ^d   Collins, Sean ^e   Dritschilo, Anatoly ^e   Lynch, John H ^f   Goldman, Radoslav ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

benign prostatic hyperplasia; case control study; estrogen metabolites; prostate cancer

Indexed keywords

16 OXOESTRADIOL; 16ALPHA HYDROXYESTRONE; 17 EPIESTRIOL; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE 3 METHYL ETHER; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; EPIESTRIOL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; HUMAN; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TANDEM MASS SPECTROMETRY;

AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; ESTROGENS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 79951530198     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21262     Document Type: Article

References (45)

1. Hsing AW, Chokkalingam AP,. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413. (Pubitemid 43253429)
2. Bosland MC,. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000; 27: 39-66.
3. Noble RL,. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37: 1929-1933. (Pubitemid 8095214)
4. Carruba G, Miceli MD, Comito L, Farruggio R, Sorci CM, Oliveri G, Amodio R, di FM, d'Amico D, Castagnetta LA,. Multiple estrogen function in human prostate cancer cells. Ann NY Acad Sci 1996; 784: 70-84. (Pubitemid 26194756)
5. Carruba G,. Estrogens and mechanisms of prostate cancer progression. Ann NY Acad Sci 2006; 1089: 201-217. (Pubitemid 47092082)
6. Leav I, Merk FB, Kwan PW, Ho SM,. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989; 15: 23-40. (Pubitemid 20214349)
7. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR,. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006; 147: 4132-4150. (Pubitemid 44274976)
8. Prins GS, Korach KS,. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73: 233-244.
9. Weihua Z, Warner M, Gustafsson JA,. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 2002; 193: 1-5. (Pubitemid 34823601)
10. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL,. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61: 5331-5335. (Pubitemid 32694904)
11. Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J, Taylor PR,. Relationships of serum androgens and estrogens to prostate cancer risk: Results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998; 7: 1069-1074. (Pubitemid 29001661)
12. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL,. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 3515-3517.
13. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL,. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990; 50: 169-173. (Pubitemid 20030013)
14. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE,. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-889.
15. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE,. Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 1410-1416. (Pubitemid 38031742)
16. Hsing AW, Comstock GW,. Serological precursors of cancer: Serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 27-32.
17. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183. (Pubitemid 351480553)
18. Adlercreutz H, Fotsis T, Hockerstedt K, Hamalainen E, Bannwart C, Bloigu S, Valtonen A, Ollus A,. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 1989; 34: 527-530. (Pubitemid 20061839)
19. Lee SH, Kim SO, Lee HD, Chung BC,. Estrogens and polyamines in breast cancer: Their profiles and values in disease staging. Cancer Lett 1998; 133: 47-56. (Pubitemid 29069110)
20. Muti P, Westerlind K, Wu T, Grimaldi T, De BJ III, Schunemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L,. Urinary estrogen metabolites and prostate cancer: A case-control study in the United States. Cancer Causes Control 2002; 13: 947-955. (Pubitemid 36169478)
21. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J,. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004; 172: 1297-1301. (Pubitemid 39249701)
22. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC,. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145: 405-409.
23. Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG,. Novel biomarkers for risk of prostate cancer: Results from a case-control study. Prostate 2009; 69: 41-48.
24. Xu X, Keefer LK, Ziegler RG, Veenstra TD,. A liquid chromatography-mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc 2007; 2: 1350-1355. (Pubitemid 46952316)
25. Church TR,. Chest radiography as the comparison for spiral CT in the National Lung Screening Trial. Acad Radiol 2003; 10: 713-715. (Pubitemid 36628919)
26. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG,. A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: Assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 2008; 17: 3411-3418.
27. Ropero AB, onso-Magdalena P, Quesada I, Nadal A,. The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids 2008; 73: 874-879.
28. Lemann J Jr, Doumas BT,. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. Clin Chem 1987; 33: 297-299. (Pubitemid 17161137)
29. Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd-Morin J, Henderson MK, Hoover RN, Veenstra TD, Keefer LK, Xu X,. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 2010; 121: 538-545.
30. Fishman J, Bradlow HL, Schneider J, Anderson KE, Kappas A,. Radiometric analysis of biological oxidations in man: Sex differences in estradiol metabolism. Proc Natl Acad Sci USA 1980; 77: 4957-4960. (Pubitemid 11236545)
31. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ,. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118-1126. (Pubitemid 26274606)
32. Matzkin H, Soloway MS,. Cigarette smoking: A review of possible associations with benign prostatic hyperplasia and prostate cancer. Prostate 1993; 22: 277-290. (Pubitemid 23176269)
33. Todorovic R, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG, Cavalieri EL,. Analysis of potential biomarkers of estrogen-initiated cancer in the urine of Syrian golden hamsters treated with 4-hydroxyestradiol. Carcinogenesis 2001; 22: 905-911. (Pubitemid 32514956)
34. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG,. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: Implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 2002; 23: 329-333. (Pubitemid 34224011)
35. Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R,. Potential biomarker for early risk assessment of prostate cancer. Prostate 2006; 66: 1565-1571. (Pubitemid 44465821)
36. Zhu BT, Conney AH,. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58: 2269-2277. (Pubitemid 28252677)
37. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP,. 2-Hydroxyestrone: The 'good' estrogen. J Endocrinol 1996; 150: S259-S265. (Pubitemid 126684587)
38. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ,. 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000; 19: 173-179. (Pubitemid 32004707)
39. Schumacher G, Neuhaus P,. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001; 127: 405-410. (Pubitemid 32524356)
40. Lavallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS,. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002; 62: 3691-3697. (Pubitemid 34728848)
41. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W,. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
42. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T,. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 493-499. (Pubitemid 29131956)
43. Etzioni R, Cha R, Feuer EJ, Davidov O,. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775-785. (Pubitemid 28485287)
44. Leymarie P, Roger M, Castanier M, Scholler R,. Circadian variations of plasma testosterone and estrogens in normal men. A study by frequent sampling. J Steroid Biochem 1974; 5: 167-171.
45. Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A,. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007; 100: 509-513. (Pubitemid 47205476)